Cipla Shares Surge 4% as Citi Eyes 90-Day Positive Catalyst Watch

Cipla shares saw a significant rally on Monday, jumping as much as 4% to hit a high of Rs 1,409 on the BSE. This bullish movement follows a strategic update from global brokerage firm Citi, which has placed the pharmaceutical giant on a "90-day Positive Catalyst Watch" while maintaining a 'Buy' rating.

US Market Triggers: Approvals and Market Dominance

The primary driver behind Citi’s optimism lies in several upcoming triggers in the United States, a critical market for Cipla. The brokerage highlighted the potential approval of gFlovent from the company’s Goa facility, a move expected to significantly boost US growth. Additionally, the anticipated launch of gVentolin is viewed as a key near-term catalyst.

Cipla's established footprint in the US is also a strength; the company's Nintedanib has already captured nearly 50% of the US market share. Following a period of relative weakness, Citi expects a revenue rebound in the US business. Furthermore, a pending re-inspection of Cipla’s Indore plant by the USFDA presents another potential upside; a favorable outcome would serve as a major positive catalyst for investors.

Domestic Resilience and Valuation Advantages

While the US market offers growth triggers, Cipla’s domestic operations provide a stable foundation. The India business, which contributes nearly two-thirds of the company's EBITDA, continues to perform strongly, supported by a recovery in its respiratory portfolio.

From a valuation perspective, Citi argues that Cipla offers attractive exposure to the Indian pharmaceutical market at a more reasonable price than its peers. For instance, Cipla's India business is valued at 7.8 times FY26 sales, which is more conservative than Mankind Pharma's valuation of 8.5 times. The stock is currently trading at 25x FY27E earnings and 21x FY28E earnings, suggesting a favorable risk-reward profile.

The optimism from analysts comes despite a challenging recent financial quarter. In Q4, Cipla reported a substantial 55% year-on-year decline in consolidated net profit, falling to Rs 555 crore from Rs 1,222 crore in the same period last year. Revenue from operations also saw a slight dip of approximately 3% YoY to Rs 6,541 crore, while EBITDA margins contracted from 22.8% to 15.2%.

However, Citi believes these earnings have likely bottomed out following the impact of gRevlimid. With easing geopolitical tensions helping to stabilize raw material costs and margins, the brokerage maintains a target price of Rs 1,700, representing a potential upside of 25.55% from current levels.

Key Takeaways

  • Near-Term Catalysts: Citi identifies US FDA approvals (gFlovent), the launch of gVentolin, and the Indore plant re-inspection as major upcoming triggers.
  • Strong Market Position: Cipla holds a 50% US market share in Nintedanib and maintains a robust domestic business that drives most of its EBITDA.
  • Attractive Valuation: Compared to domestic peers like Mankind, Cipla offers a more reasonable valuation for exposure to the growing Indian pharma market.